tolerogenic dendritic cells
Phase 2Biologic
tolerogenic dendritic cells is one of 35 biologic programs targeting Multiple Sclerosis. It is currently in Phase 2.
1
Indications
5
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
145 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Versed
CConrado Roberto Hoffmann Filho
Phase 3
Frexalimab
SanofiPhase 3
Clemastine Fumarate
NovartisPhase 3
Recombinant Zoster Vaccine
MMAXVAX Biotechnology Limited Liability Company
Phase 3
MRI Contrast-Enhancing Agents
SanofiPhase 3
PBR06
UUniversity Hospital, Bordeaux
Phase 3
Flomax
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Sclerosis2 trials
Safety and Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for tolerogenic dendritic cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity Hospital, Antwerp